Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research

Volumn 64, Issue 2, 2004, Pages 672-677

  Donato, Nicholas J ^a   Wu, Ji Y ^a   Stapley, Jonathan ^a   Lin, Hui ^a   Arlinghaus, Ralph ^a   Aggarwal, Bharat ^a   Shishodin, Shishir ^a   Albitar, Maher ^a   Hayes, Kimberly ^a   Kantarjian, Hagop ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PHOSPHOTRANSFERASE;

ADULT; ARTICLE; BLOOD SAMPLING; CASE REPORT; CELL VIABILITY; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION; LEUKEMIA, MYELOID, CHRONIC; PHILADELPHIA CHROMOSOME; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TERMINAL REPEAT SEQUENCES;

EID: 9144234689     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1484     Document Type: Article

References (35)

1. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med., 340: 1330-1340, 1999.
2. Faderl, S. Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., and Kantarjian, H. M. The biology of chronic myeloid leukemia. N. Engl. J. Med., 341: 164-172, 1999.
3. Daley, G. Q., Van Etten, R. A., and Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (Wash. DC). 247: 824-830, 1990.
4. Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P. K., and Groffen, J. Acute leukaemia in bcr/abl transgenic mice. Nature (Lond.), 15; 344: 251-253, 1990.
5. Sawyers. C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., Ottmann, O. G., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a II phase study. Blood, 99: 3530-3539, 2002.
6. Talpaz, M., Silver, R. T., Druker, B. J., Goldman, J. M., Gambacorti-Passerini, C., Guilhot, F., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronie myeloid leukemia: results of a phase 2 study. Blood, 99: 1928-1937, 2002.
7. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344: 1038-1042, 2001.
8. Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., and Sawyers, C. L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2: 117-125, 2002.
9. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash. DC), 293: 876-880, 2001.
10. Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., and Hughes, T. P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99: 3472-3475, 2002.
11. Hochhaus, A., Kreil, S., Corbin, A. S., La Rosee, P., Muller, M. C., Lahaye, T., Hanfstein, B., Schoch, C., Cross. N. C., Berger, U., Gschaidmeier, H., Druker, B. J., and Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (571) therapy. Leukemia (Baltimore), 6: 2190-2196, 2002.
12. Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., and Talpaz, M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI-571. Blood, 101: 690-698, 2003.
13. Donato, N. J., Wu, J. Y., Zhang, L., Kantarjian, H., and Talpaz, M. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor β-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood, 97: 2846-2853, 2001.
14. Albitar, M., Manshouri, T., Shen, Y., Liu, D., Beran, M., Kantarjian, H. M., Rogers, A., Jilani, I., Lin, C. W., Pierce, S., Freireich, E. J., and Estey, E. H. Myelodysplastic syndrome is not merely "preleukemia". Blood, 100: 791-798, 2002.
15. Zhao, L., Hayes, K., Khan, Z., and Glassman. A. Spectral karyotyping study of chromosome abnormalities in human leukemia. Cancer Genet. Cytogenet., 127: 143-147, 2001.
16. Donato, N. J., Yan, D. H., Hung, M. C., and Rosenblum, M. G. Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells. Cell Growth Differ., 4: 411-419, 1993.
17. Bharti, A. C., Donato, N., Singh, S., and Aggarwal, B. B. Curcumin (diferuloylmethane) downregulates the constitutive activation of nuclear factor κB and IκBα kinase in human multiple myeloma cells leading to suppression of proliferation and induction of apoptosis. Blood, 101: 1053-1062, 2003.
18. Guo, J. Q., Lin, H., Kantarjian, H., Talpaz, M., Champlin, R., Andreeff, M., Glassman, A., and Arlinghaus, R. B. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia (Baltimore), 16: 2447-2453, 2002.
19. Nishimura, J., Okamura, J., Shibata, K., Takahira, H., Yufu, Y., Kato, S., Hirata, J., Umemura, T., and Nawata, H. Two bcr/abl fusion gene products, P210bcr/abl and P190bcr/abl, are equally sensitive to the protein tyrosine phosphatase of mature granulocytes, Int. J. Hematol., 54: 471-478, 1991.
20. Lionberger, J. M., Wilson, M. B., and Smithgall, T. E. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J. Biol. Chem., 275: 18581-18585, 2000.
21. Roginskaya, V., Zuo, S., Caudell, E., Nambudiri, G., Kraker, A. J., and Corey, S. J. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia (Baltimore), 13: 855-861, 2001.
22. Zhu, J., and Emerson, S. G. Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene, 21: 3295-3313, 2002. ]
23. Baud, V., and Karin, M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol., 11: 372-377, 2001.
24. Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T., and Gerritsen, M. E. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem., 272: 21096-21103, 1997.
25. Weisberg, E., and Griffin, J. D. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood, 95: 3498-3505, 2000.
26. Mahon, F. X., Deininger, M. W., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., and Melo, J. V. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 96: 1070-1079, 2000.
27. Jiang, X., Ng, E., Yip, C., Eisterer, W., Chalandon, Y., Stuible, M., Eaves, A., and Eaves, C. J. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Blood, 100: 3731-3740, 2002.
28. Dorsey, J. F., Cunnick, J. M., Lanehart, R., Huang, M., Kraker, A. J., Bhalla, K. N., Jove, R., and Wu, J. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia (Baltimore), 16: 1589-1595, 2002.
29. O'Dwyer, M. E., Mauro, M. J., Kurilik, G., Mori, M., Balleisen, S., Olson, S., Magenis, E., Capdeville, R., and Druker, B. J. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood, 100: 1628-1633, 2002.
30. Hernandez-Boluda, J. C., Cervantes, F., Costa, D., Carrio, A., and Montserrai, E. Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature. Leuk, Lymphoma, 38: 83-90, 2000.
31. Gelfanov, V. M., Burgess, G. S., Litz-Jackson, S., King, A. J., Marshall, M. S., Nakshatri, H., and Boswell, H. S. Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor KB-mediated antiapoptosis involving c-IAP2. Blood, 98: 2508-2517, 2001.
32. Holyoake, T. L., Jiang, X., Jorgensen, H. G., Graham, S., Alcom, M. J., Laird, C., Eaves, A. C., and Eaves, C. J. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood, 97: 720-728, 2001.
33. Wilson, M. B., Schreiner, S. J., Choi, H. J., Kamens, J., and Smithgall, T. E. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene, 21: 8075-8088, 2002.
34. Arai, A., Kanda, E., Nosaka, Y., Miyasaka, N., and Miura, O. CrkL is recruited through its SH2 domain to the erythropoietin receptor and plays a role in Lyn-mediated receptor signaling. J. Biol. Chem., 276: 33282-33290, 2001.
35. Golas, J. M., Arndt, K., Etienne, C., Lucas, J., Nardin, D., Gibbons, J., Frost, P., Ye, F., Boschelli, D. H., and Boschelli, F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res., 63: 375-381, 2003.